Remimazolam versus sevoflurane for maintenance of anesthesia and postoperative nausea and vomiting in laparoscopic gynecologic oncology surgery: a randomized controlled trial
In brief
Remimazolam cuts 24-hour nausea and vomiting from 45% to 21%
In a single-center randomized trial of 113 patients having laparoscopic gynecologic cancer surgery, postoperative nausea and vomiting within 24 hours occurred in 21% with remimazolam anesthesia versus 45% with sevoflurane. The difference suggests remimazolam could reduce this common complication, but the reduction was smaller than the trial had planned for, and its clinical importance needs further evaluation.
- Journal
- BMC anesthesiology (Q1)
- Published
- 21 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Chaopeng Ou, Xuanwei Huang, Hongyu Wei, Yingjun Zhang, Jingdun Xie
- PMID
- 42806304
- DOI
- 10.1186/s12871-026-04251-7
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (top studies of the week, 4 October 2026): Remimazolam reduces PONV vs sevoflurane in laparoscopic gyn surgery
Abstract
BACKGROUND: Postoperative nausea and vomiting (PONV) remains a frequent complication following laparoscopic gynecologic surgery, particularly in female patients with multiple established risk factors receiving volatile anesthetics. Remimazolam, a short-acting benzodiazepine, is an alternative intravenous anesthetic, but its effect on PONV compared with sevoflurane remains unclear. METHODS: In this single-center, prospective randomized controlled trial, 116 patients were enrolled and 113 were included in the final analysis (sevoflurane n = 56, remimazolam n = 57). Patients were randomly assigned to receive either sevoflurane-based or remimazolam-based maintenance of anesthesia. The primary outcome was the incidence of PONV within 24 h after surgery. Exploratory analyses were performed to evaluate the associations between PONV and perioperative factors, including intraoperative hemodynamic variables, fluid administration, and opioid consumption. RESULTS: The incidence of PONV within 24 h was lower in the remimazolam group than in the sevoflurane group (21.1% vs. 44.6%, P = 0.013). Remimazolam was associated with reduced PONV incidence compared with sevoflurane. Although remimazolam was associated with higher intraoperative mean arterial pressure (MAP), exploratory analyses did not identify a significant association between intraoperative MAP and PONV. The observed absolute reduction in PONV incidence was 23.6%, which was slightly lower than the predefined effect size used for sample size estimation. CONCLUSIONS: Remimazolam-based anesthesia was associated with a lower incidence of PONV compared with sevoflurane in patients undergoing laparoscopic gynecologic oncology surgery. Although statistically significant, the observed reduction was slightly smaller than the effect size predefined during sample size estimation, and its clinical relevance requires further evaluation. TRIAL REGISTRATION: ChiCTR2600128362. (Retrospectively registered). The initial registration date was 07/17/2026.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.